# ABclonal

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/abclonal

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.abclonal.com.cn
- Total disclosed funding: $373M
- Latest round: Series D (Dec 8, 2021)
- Investors on record: 24

## About

Based in Wuhan, China, ABclonal, Inc. is a biotechnology company that provides medical products and contract research organization (CRO) services. The company has approximately 78 employees and has raised a total of CNY 600 million in 5 venture funding rounds. In 2011, the company launched the human genome antibody library research and development plan. In 2017, the company introduced molecular enzymes and NGS library building kit products. In 2020, the company has developed raw materials for COVID-19 nucleic acid detection, antibody antigen detection and proteinase K products. In 2021, the company acquired Yurogen.
 
The company manufactures laboratory supplies and provides CRO services, serving global scientific research institutions, drug research and development institutions, and diagnostic industry businesses.

The company generates revenue through the sale of antibody products. Clients can place their orders through the company’s website.

Going forward, ABclonal, Inc. will look to expand its biology reagent products.

## Funding rounds

- Series D, Dec 8, 2021, $188M — Hong Shan, WI Harper Group, CITIC Securities, Shandong High-tech Investment Corporation, CMB International Asset Management, Loyal Valley Capital, Taikang Investment, Jinkong Qiyuan Capital, FER Capital, Beijing Zhiming Haojin Investment Management, Jingming Capital, Jiangsu Zhiyuan Capital Management
- Series C, Feb 22, 2021, $93M — Hong Shan, Shandong High-tech Investment Corporation, LYFE Capital, Sigma Square Capital, Kinghall Ventures
- Series C, Dec 18, 2020, $92M — Hong Shan, Oriza Holdings, Shandong High-tech Investment Corporation, LYFE Capital, Sigma Square Capital, Jinyuan Kuntong Equity Investment Management, Xiamen C&D Emerging Industry Equity Investment
- Series B, Aug 15, 2019 — Wuhan Ruichuang Hengyi Investment Management
- Series A, Jan 15, 2019 — Huaxin Capital, Jinyuan Kuntong Equity Investment Management, Jinkong Qiyuan Capital, Funway Capital
- Series A, Mar 9, 2018 — Sigma Square Capital
- Angel, Jun 14, 2016 — Huagong Venture Capital, Guanggu Rencai Fund, Shanghai Qianshi Investment Management

## Investors

- Huagong Venture Capital (https://capitalatlas.ai/funds/huagong-venture-capital) — Angel
- Guanggu Rencai Fund (https://capitalatlas.ai/funds/guanggu-rencai-fund) — Angel
- Shanghai Qianshi Investment Management — Angel
- Sigma Square Capital (https://capitalatlas.ai/funds/sigma-square-capital) — Series A, Series C
- Huaxin Capital — Series A
- Jinyuan Kuntong Equity Investment Management (https://capitalatlas.ai/funds/jinyuan-kuntong-equity-investment-management) — Series A, Series C
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series A, Series D
- Funway Capital (https://capitalatlas.ai/funds/funway-capital) — Series A
- Wuhan Ruichuang Hengyi Investment Management (https://capitalatlas.ai/funds/wuhan-ruichuang-hengyi-investment-management) — Series B
- Hong Shan — Series C, Series D
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series C
- Shandong High-tech Investment Corporation (https://capitalatlas.ai/funds/shandong-high-tech-investment-corporation) — Series C, Series D
- LYFE Capital — Series C
- Xiamen C&D Emerging Industry Equity Investment (https://capitalatlas.ai/funds/xiamen-c-d-emerging-industry-equity-investment) — Series C
- Kinghall Ventures — Series C
- WI Harper Group (https://capitalatlas.ai/funds/wi-harper-group) — Series D
- CITIC Securities — Series D
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series D
- Loyal Valley Capital (https://capitalatlas.ai/funds/loyal-valley-capital) — Series D
- Taikang Investment (https://capitalatlas.ai/funds/taikang-investment) — Series D
- FER Capital (https://capitalatlas.ai/funds/fer-capital) — Series D
- Beijing Zhiming Haojin Investment Management — Series D
- Jingming Capital (https://capitalatlas.ai/funds/jingming-capital) — Series D
- Jiangsu Zhiyuan Capital Management — Series D